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Measurement of the glomerular filtration rate (GFR) is the
gold standard for precise assessment of kidney function.
A rapid, point-of-care determination of the GFR may provide
advantages in the clinical setting over currently available
assays. Here we demonstrate a proof of principle for such an
approach in a pig and dogs, two species that approximate
the vascular access and GFR results expected in humans.
In both animal models, a sub-millimeter optical fiber that
delivered excitation light and collected fluorescent emissions
was inserted into a peripheral vein (dog) or central venous
access (pig) by means of commercial intravenous catheters.
A mixture of fluorescent chimeras of a small freely filterable
reporter and large non-filterable plasma volume marker were
infused as a bolus, excited by light-emitting diodes, and the
in vivo signals detected and quantified by photomultiplier
tubes in both species in less than 60min. Concurrent
standardized 6-h iohexol plasma kidney clearances validated
the accuracy of our results for both physiologic and a chronic
kidney disease setting. Thus, our ratiometric technique allows
for both measurement of plasma vascular volume and highly
accurate real-time GFR determinations, enabling clinical
decision making in real time.
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Quantifying kidney function and/or injury remains a vexing
and increasingly important clinical problem. This results in
the inability to diagnose and stratify patients with acute
kidney injury or chronic kidney disease appropriately, follow
progression of the disease, or response to therapy.1–4
Measurement of glomerular filtration rate (GFR) is the
gold standard for precise assessment of kidney function.1
There are many well-known potential clinical applications in
which GFR measurement could directly improve patient
management. For example, GFR may be beneficial while
determining drug-dosage adjustments in patients with
acute or chronic kidney dysfunction, as a screening test for
hospital-acquired kidney injury in patients with or without
preexisting kidney damage, to assess therapeutic response or
rate of progression of kidney disease, to monitor patients
requiring repeated administration of nephrotoxic drugs,
and potentially as an indirect assessment of visceral
organ perfusion, such as during prolonged anesthesia.1–3,5
Despite these potential roles for GFR determination in
optimization of patient care, quantification with validated
GFR markers is uncommonly performed in the clinical
setting because existing GFR measurement techniques
require several blood draws over an extended period of time,
administration of markers that require specialized prepara-
tion, handling (that is, radionuclides), or assays (that is,
inulin and iohexol), or submission of samples to external
laboratories.1
Attempts have been made using serum creatinine or
cystatin C to estimate GFR, the so-called estimated GFR;
however, accuracy, the dependence on a stable serum
creatinine, and decreased reliability outside of a narrow
range of 20–60 (ml/min per 1.73 m2) have greatly limited the
utility of this approach. In addition, the necessity of having
quantitative analysis of GFR in therapeutic trials is well
established.6 Therefore, we hypothesized that the develop-
ment of a point-of-care bedside fluorescent technique, with
in vivo rapid detection and instantaneous calculation of GFR,
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would allow for the rapid, reproducible, inexpensive, safe,
and patient-friendly determination of GFR in a time frame
necessary to make appropriate clinical decisions. We
demonstrate here that the portable analyzer developed for
this purpose allowed point-of-care determination of GFR
within 60 min of administration of the fluorescent conju-
gates, with minimal adverse effects and excellent agreement
with the 6-h iohexol-based GFR technique. Our results
provide proof of principle for the use of this ratiometric
analyzer for rapid determination of GFR in larger species that
approximate the vascular access and GFR results expected in
humans. The principle governing this unique ratiometric
fluorescent approach to quantifying kidney function can be
expanded to other organs and many other processes allowing
for improved accuracy and far more rapid clinical decision
making.
RESULTS
Design of the ratiometric optical fiber system
Translation of our previously described two-photon techni-
que7 to the clinical situation required development of a
system capable of generating and delivering two excitation
sources and quantifying the detection of the corresponding
emissions. The ratiometric fiber optical system developed
contained blue (center peak 490 nm, full width half
maximum 30 nm, Roithner Laser Technik) and amber (center
peak 590 nm, full width half maximum 20 nm) light-emitting
diodes (LEDs), which provided excitation illumination for
fluorescein (green) and Texas Red fluorescent conjugates,
respectively (Figure 1a and b). A condenser, consisting of a
pair of plano-convex lenses, placed after each LED provided a
nearly collimated beam, and stray light was reduced with
apertures placed both before and after the condensers. The
excitation bandpass filters were Semrock FF475/20 and
FF579/34 for the blue and amber LEDs, respectively. After
passing through these designated excitation filters, the two
nearly collimated beams were merged at the excitation
dichroic mirror (Semrock FF520-Di01) that reflects blue and
transmits amber. A dual-band dichroic mirror (Semrock
FF505/606-Di01) then reflected the merged excitation light
901 toward a biconvex fiber lens (LB1761-A, Thorlabs) that
focused the beam onto a 0.75 mm optical fiber placed behind
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Figure 1 |Design of the ratiometric optical fiber system. (a) Optical layout. 1a and 1b, light-emitting diodes (LED) power supplies; 2a and
2b, amber and blue LEDs, respectively; 3a and 3b, collimating condensers with apertures; 4a and 4b, excitation bandpass filters; 5, excitation
dichroic mirror; 6, dual-band dichroic mirror; 7, fiber lens with aperture; 8, fiber adapter; 9, optical fiber; 10, catheter; 11, emission
dichroic mirror; 12a and 12 b, photomultiplier tube (PMT) focus lenses with apertures; 13a and 13b, emission filters; 14a and 14b, PMTs.
(b) Cross-section showing optical components. (c) Electronic system of the device. SPI, serial peripheral interface.
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a 1 mm aperture. The insertion of the fiber optic cable into the
vein was facilitated by passing it through a standard
angiocatheter. The length of the optical fiber was designed
such that it extends B1 cm beyond the distal tip of the
intended intravenous catheter. The mixed fluorescence signal
returned by the fiber passed through the same dual-band beam
splitter that reflected the excitation wavelengths. The red and
green emissions were separated by a Semrock FF560-Di01
dichroic mirror. The emission single bandpass filters for the
green and red channels were a Semrock FF01 525/39 and a
Chroma 640/50 m, respectively. A side-on Hamamatsu photo-
multiplier tube (PMT) H9650-20 was used for both channels.
Electronic system
The electronic system of the device is shown in Figure 1c. The
LEDs were driven by a voltage-controlled current source built
around a MOSFET and operational amplifier. The control
voltage was provided by the digital-to-analog converter
(TLC5628, Texas Instruments) that communicated with the
microprocessor (PIC18F4620, Microchip) via the serial
peripheral interface port. The modulated LEDs provided
125 ms illumination pulses. Fluorescence emissions from the
two conjugates were collected by two PMTs. The gain of
the PMTs was controlled by the control voltage that was
generated by another digital-to-analog converter controlled
by the microprocessor. The analog signal from each PMT was
filtered before feeding it into a 16-bit Delta-Sigma modula-
tion analog-to-digital converter (ADS1174, Texas Instru-
ments) operating at 128 samples per second. Accurate timing
of the LED on/off time with synchronization of the A/D
readings allowed data averaging and subtraction of ambient
light and dark current errors, producing a final sampling
rate of 1 Hz. The final data were transmitted via a USB port
to a laptop computer.
Determination of GFR in large animals
Fluorescence-vs.-time curves were successfully generated in a
pig for both the small and large dextran conjugates (Figure 2).
These fluorescent conjugates have previously been used in an
in vivo rat model using two-photon microscopy.7 Although
the signal from the large nonfilterable plasma volume
‘marker’ dextran (red channel) remained stable over time,
the signal of the filterable 5 kDa fluorescein isothiocyanate
(FITC)-inulin (green channel) ‘reporter’ initially decreased
rapidly because of combined inter-compartment redistribu-
tion (movement into the extracellular space) and kidney
clearance, followed by the later slower decrease in fluores-
cence solely due to kidney clearance. The normalized
fluorescence ratio-vs.-time curve produced by calculation of
the green/red ratio is shown in Figure 2 along with the
raw data from both channels shown in the figure inset.
Plasma volume, determined by dilution of the large dextran
molecule, was 1012.3 ml, or 3.4% of total body weight.
Calculated GFR from the serial iohexol samples was 2.02 vs.
2.11 ml/min/kg as determined using the ratiometric
two-compartment method in 60 min.
Fluorescence-vs.-time curves were also reproducibly
generated in dogs for both the small and large dextran
conjugates with peripheral venous access via the cephalic
vein. An example of a dog under physiological conditions
with mild sedation (see Materials and Methods) is shown in
Figure 3a. More frequent and higher spike artifacts, which
were reduced in the green/red ratio curve, corresponded to
movement by the non-anesthetized dog during data collec-
tion. An example of a dog with a reduced GFR, anesthetized
using isoflurane, is presented in Figure 3b, showing a slower
fluorescence ratio decay, an indication of a slower kidney
clearance, compared with the curve from the normal dog
shown in Figure 3a. Table 1 shows GFR values obtained using
three different techniques from four different dogs, three of
which had normal kidney clearance. The values contained in
the bottom row were generated from a dog with chronic
kidney disease. Plasma volumes obtained using the large
dextran were also shown in the table. No systemic toxicity
was noted in these studies.
DISCUSSION
Translation of fluorescent technology into quantitative
in vivo clinical applications has been rare, despite the
extremely high sensitivity of fluorescence techniques, because
of its complex and platform-dependent nature.8 As a result,
accurate determination of the concentration of fluorescent
molecules under in vivo conditions is usually very difficult.
With this in mind, we felt that the ideal starting point for
clinical translation of fluorescent technology was with the
quantification of GFR using the ratiometric technique.7,9 In
addition to being able to use inert and highly water-soluble
molecules, such as dextrans, for our parent molecules, the
fluorescent labeling of dextrans is well worked out and offers
high conjugation ratios.7 This allowed for very small amounts
of fluorescent dextrans to be used in our studies, and has
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Figure 2 |Quantifying plasma volume and glomerular
filtration rate in a pig using fluorescent inulin and dextran.
Time courses for the reporter 5 kDa fluorescein isothiocyanate-
inulin and the marker 150 kDa Texas Red dextran after a
co-injection into an Osabaw swine. The fluorescence ratio
(inulin/dextran) data (dots) were fitted to a bi-exponential
equation and the fitted curve is shown as a solid line. The
original data that generated the ratio are shown in inset.
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important clinical safety and financial implications. In
addition, the use of one fluorescent chimera as a plasma
volume marker, and a second freely filterable small highly
fluorescent reporter molecule to quantify the rate of plasma
clearance as an assay for GFR, replaced the necessity of
concentration measurements of the filtration reporter with
relative fluorescence intensity determinations. Calibration of
the detection device and plasma volume marker fluorescent
dextran must still be accomplished. However, the relatively
stable impermeable nature of this large marker molecule
allows for accessing the plasma volume accurately. For the
studies presented here, the use of the large dextran marker
was in transition from a very large molecule (500 kDa)
labeled with Texas Red in our rat studies7 to a more clinically
acceptable marker yet still with a size preventing movement
into the extravascular space. We did not go smaller than
150 kDa to avoid movement of the marker molecule into the
extravascular space, especially in disease states such as sepsis.
We have also substituted a novel dye, 2-sulfohexamine-
rhodamine-dextran, with reproducible production character-
istics allowing for clinical use not possible with available
rhodamine derivatives. We also converted to a freely filterable
dextran, with the same molecular weight as that of inulin,
for labeling with FITC instead of inulin for reasons
previously explained.7 We previously showed that the
5 kDa-FITC-dextran and 5 kDa FITC-inulin produced vir-
tually identical decay curves and yielded the same GFR value
in the same rat, indicating that there was no difference in
the non-renal clearance between these two compounds. This
contradicts the observation by Mehvar et al.10 who reported
high non-renal clearance for a 4 kDa small dextran. If the
non-renal clearance of our small dextran conjugate was indeed
substantially higher than inulin, we would have obtained
much higher GFR values. However, we have never seen this
either with the fiberoptic device or spectroscopy approach, in
which we used plasma samples for up to 6 hours.
The rapid and accurate determination of GFR, the
primary functional marker for the kidney, has been a clinical
goal for over 50 years. The cumbersome, time-consuming,
and expensive techniques presently available have not met
this important clinical need. Development and use of
estimating formulas based on serum creatinine or cystatin
C have been disappointing and also have not met this need
for several well-explained reasons.11 Therefore, the develop-
ment of a rapid, accurate, safe, easy, and inexpensive
technique has high clinical importance both in and outside
of the hospital.
Following up on our previous two-photon microscopic rat
studies,7 we have now translated our approach to large
animals with the development of an optical catheter and
fluorescent analysis device. We have demonstrated that using
this novel method employing inert fluorescent size-specific
dextran molecules we were able to accurately, reproducibly,
and rapidly quantify the GFR in dog and pig models in real
time at the point of contact. The GFR values obtained using
the device showed excellent agreement with that from the
established iohexol approach that required 6 h of repeated
plasma sampling and extensive laboratory processing before
GFR calculations. We also demonstrated that the technique
was accurate in a dog with severely reduced kidney function.
Table 1 | Normal and CKD GFR of dogs
Dog ID
GFR (ml/min/kg)
by spectroscopy
GFR (ml/min/kg)
by the device
GFR (ml/min/kg)
by iohexol Condition
Weight
(kg)
Plasma
volume (ml)
1 4.06 4.25 4.4 Normal 22.5 1344
2 3.76 4.8 4.5 Normal 33 1838
3 3.77 3.35 4.07 Normal 27.3 1352
4 1.27 1.19 1.45 CKD 29.8 1482
Abbreviations: CKD, chronic kidney disease; GFR, glomerular filtration rate.
GFR values obtained by three different techniques along with plasma volumes from three normal dogs and one CKD dog are shown. During the tests dogs 1 and 2 were with
mild sedation with 0.1mg/kg intravenously administered acepromazine; dogs 3 and 4 were anesthetized using isofluorane.
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Figure 3 |Quantifying plasma volume and glomerular filtration rate in dogs using fluorescent dextrans. The data shown in a and b
were generated from a dog under physiological conditions and a chronic kidney disease model, respectively. The 5/150 kDa ratio data (dots)
from the optical device were fit to a bi-exponential equation. In each case, the fitted curve is shown as a solid line. A good overlap is seen
between the device data points and the plasma fluorescence of the 5 kDa fluorescein isothiocyanate-dextran (triangles) from a
spectroscopic analysis. The original data that generated the ratio are shown in the inset in each panel.
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There are several major advantages to the use of a point-
of-care ratiometric device based on intravascular readouts
using fluorescently labeled dextrans. First, the real-time
determination of GFR is based on a two-compartment model,
thus eliminating the long time necessary for a one-compart-
ment model that is based on elimination from the entire
extracellular space.12–16 It is also more rapid than a continuous
infusion approach that entails even longer time before a
dynamic plasma equilibrium can be established between
infusion and clearance.17–19 The ability of the rapid technique
to quantify rapidly changing GFR has been previously
reported for acute kidney injury in rats.7 Second, the safety
of dextrans seems likely, as dextrans have been used clinically
for many years in very large doses compared with the small
amount used in this study.20–22 Third, dextrans can be
correctly sized, highly conjugated with fluorescent molecules,
and are very soluble in plasma, making them ideal markers.7
The extremely high sensitivity of the intravascular optical
probe further reduces the amount of fluorescent injectate
needed. The nearly continuous plasma data collection provides
an unprecedented rich source of data for calculation of GFR.
As we demonstrated recently, using two-photon microscopy in
rats, the rapid sampling rate of data collection during the
early time course is essential to help shorten the time needed
for an accurate determination of GFR.7 This can be easily
achieved with the fiber optical catheter and detection device.
In addition, the larger fluorescent marker serves to rapidly
quantify plasma volume, an important clinical parameter
on its own, and eliminates the need for determining plasma
concentrations of the smaller reporter molecule.7 Finally, the
larger fluorescent marker, when used to develop the ratio,
minimizes signal noise and detection abnormalities.7,9
The present technique has great utility for measuring GFR
in many clinical situations. However, no situation is as
important as acute kidney injury where a rapid diagnosis and
quantification of the extent of injury are necessary. As both
serum cystatin C and creatinine are slow to rise and not
in equilibrium during the early phase of acute kidney
injury, estimating equations are useless. Although structural
biomarkers are being developed, the inability of these
biomarkers to quantify the extent of injury will limit their
effectiveness of clinical approaches to therapy.
The present approach does have limitations. First, an
indwelling venous catheter is necessary for insertion of the
optical probe and likely requires a vein size of 2.5 mm or
larger. Recent studies in rats used a noninvasive detector
of fluorescence to determine the GFR in rats.15,16 However,
much longer time is required as this is dependent on
extracellular detection and clearance of the small molecule
used and not vascular clearance as performed in our studies
using a two-compartment model. In addition, excessive
amount of fluorescent marker is needed because of the loss of
illumination and fluorescence emission in the tissue. For our
studies, we have specifically designed the system so that
a standard 18-gauge peripheral IV catheter will work. The
study still takes about an hour, but we see no way to improve
upon this. However, the data are obtained at the point-of-
care, thus eliminating time-consuming laboratory proce-
dures. Finally, motion artifacts due to animal movement have
been a concern, but the ratiometric approach has greatly
reduced this concern. In humans, we believe that there will
be minimal spontaneous movement during the test, thus
resulting in less optical noise from catheter movement.
The fluorescent approach presented here can be readily
adapted for additional clinical studies. In addition, pharma-
cokinetic studies of fluorescently labeled molecules can also
be accomplished rapidly with far richer data than allowed for
by repeated blood sampling. Finally, development of specific
fluorescent reporter molecules based on well-documented
preclinical studies should allow for organ-selective evaluation
using the approach delineated here.
MATERIALS AND METHODS
Animal handling and data collection
Protocols involving animals were approved by an institutional
animal care and use committee and complied fully with recom-
mendations outlined by the National Research Council and
American Veterinary Medical Association.23,24 For the pig study,
an adult 29.5 kg female Ossabaw miniature swine was anesthetized
using 2.5–3.5% isoflurane, and the optical fiber was inserted through
a central venous catheter placed in the external jugular vein.
Following determination of background fluorescence, 5 ml of
350 mg iodine per ml iohexol (Omnipaque, GE Healthcare,
Princeton, NJ) was injected as a bolus via a peripheral intravenous
catheter, followed immediately by 5 ml of a fluorescent conjugate
mixture containing 75 mg 5 kDa FITC-inulin (Sigma, St Louis, MO)
and 75 mg 150 kDa Texas Red dextran (a gift from FAST,
Indianapolis, IN). For the dog pilot study, peripheral 18-g, 1.2-
inch intravenous catheters were placed in the left cephalic and left
lateral saphenous veins of dogs. Following mild sedation with
0.1 mg/kg intravenously administered acepromazine or anesthetiza-
tion with isofluorane, 0.9% NaCl equal to 2.5% of body weight was
administered over 10 min; dogs with mild sedation were then
minimally restrained in lateral recumbency for the entire procedure.
The optical fiber was inserted through the cephalic catheter and,
following determination of background fluorescence using the
ratiometric analyzer, an intravenous bolus injection of 4 ml of
350 mg iodine per ml iohexol through the saphenous catheter was
administered, immediately followed by a mixture of 69–175 mg
5 kDa fluorescein-dextran and 34–75 mg 150 kDa 2-sulfohexamine-
rhodamine-dextran dextran obtained from FAST.
EDTA-anticoagulated blood samples were collected immediately
before and 30, 60, 90, 120, 180, 240, and 360 min, or immediately
before and 5, 10, 20, 60, 180, 240, and 360 min following injections
in the pig and dog, respectively. All blood samples were centrifuged
within 3 h of collection and supernatants stored at 20 1C until
analysis. Fluorescent conjugate concentrations were determined
using an M5 SpectraMax spectrophotometer (Molecular Devices,
Sunnyvale, CA); iohexol concentrations were determined as previously
reported.25,26 Data collection using the ratiometric device was begun
B1 min before the infusion of fluorescence conjugates, and continued
forB60 min. Sampling rate was 128 Hz at a rate of 1 point/s, and the
data from each channel, as well as the green/red fluorescence ratio,
were converted by the analyzer into smoothed real-time fluorescence
curves, which were continuously displayed during data collection.
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Pharmacokinetic modeling and GFR determination
A two-compartment pharmacokinetics model, as described
previously,7,26–29 was used for determination of GFR. Pig GFR was
determined by the iohexol method described previously,24,25 as well
as the fiberoptic ratiometric method described below. In addition to
these two techniques, dog GFR was also determined spectros-
copically using the plasma concentrations of small fluorescent
conjugate.27 Conventional approach to determine GFR requires
determinations of the plasma concentrations of the GFR reporter
from multiple blood samples drawn over 5–6 h. As was demon-
strated recently,7 both requirements can be eliminated by using the
ratiometric two-compartment model. We applied this approach,
established using two-photon microscopy in rats, to the current
studies in large animals using the optical fiber device described
above. In brief, following bolus injection, the infused smaller
dextran molecules are cleared by the kidneys or redistribute from the
vascular into the interstitial space, but do not move intracellularly;
the large dextran molecules are retained in the vascular space. The
time course of the background-corrected fluorescence ratio of the
freely kidney filterable reporter (5 kDa fluorescein-dextran or 5 kDa
FITC-inulin) to the nonfilterable vascular marker (150 kDa Texas
Red dextran or 5 kDa 2-sulfohexamine-rhodamine–dextran) was
fitted to a bi-exponential equation (Equation 1) using the Sigma
plot program to obtain the amplitudes and decay constants:
R ¼ Aeat þ Bebt ð1Þ
where R is the green/red fluorescence ratio, A and B are the initial
amplitudes, and a and b are the decay constants. GFR was then
calculated using the equation:
GFR ¼ V
A
AþB
a þ
B
AþB
b
ð2Þ
where the plasma volume V was determined via spectrophotometry
(SpectraMax M5, Molecular Devices) by measuring the plasma
concentration of the nonfilterable large dextran 10 min post
intravenous injection, thus eliminating the need to quantify plasma
concentration of the GFR reporter over time.7
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